Biotech / Clinical data
Xencor picks 400 mcg/kg XmAb819 dose on a 45.5% response rate from 11 patients
The 400 mcg/kg expansion cohort showed a 45.5% confirmed objective response rate and 55% including unconfirmed responses, with an 82% six-month PFS estimate. The 8-K carried no quarterly revenue or earnings figures.